
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics is viewed favorably because FT819 is showing favorable safety, with lower AESI rates and no ICANS or IEC-HS, while early efficacy in lupus nephritis includes 2/2 renal responses after bendamustine conditioning and durable benefit beyond 6 months. The company’s outpatient administration and use in community hospitals suggest a more accessible commercial profile than TCEs or autologous cell therapies, and the registrational Phase II RECLAIM-LN study in 53 patients with a 6-month CRR endpoint provides a clear catalyst path. Beyond FT819, IND clearance for FT839 and early antitumor activity for FT836 broaden the pipeline, supporting a higher projected enterprise value of $1.09 billion versus $766 million.
Bears say
Fate Therapeutics is exposed to substantial fundamental risk because its iPSC-derived NK and T-cell candidates could fail clinically, run into regulatory setbacks, or prove commercially unviable. The autoimmune disease market is highly competitive, and stronger-than-expected competitor dynamics could erode any potential advantage while a more unfavorable political and commercial environment could further weaken adoption prospects. In addition, the company will likely require additional cash and may face future litigation, which raises financing and execution risk on top of already uncertain development outcomes.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Fate Therapeutics (FATE) Forecast
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares